Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Financing › Details

Commit Biologics–SEVERAL: investment, 202405 seed financing round €16m led by Bioqube Ventures + Novo Holdings

 

Period Period 2024-05-09
Organisation Money taker SEVERAL
Products Product BiCE™ platform (Bispecific Complement Engaging platform)
  Product 2 venture capital
Persons Person Bakker, Jeroen (Novo Group 202010 at Novo Seeds)
  Person 2 Verhelst, Roderick (Bioqube Ventures 202405 Principal)
     

Commit Biologics ApS. (5/9/24). "Press Release: Commit Biologics Launches with €16m Seed Financing to Pioneer Complement System Activation to Treat Cancer and Autoimmune Disease". Aarhus.

> Financing led by Bioqube Ventures and Novo Holdings

> Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases

> Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells

> Spin-out from Aarhus University in Denmark, a world leader in complement structural biology


Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdings.

Commit plans to accelerate development of its Bispecific Complement Engaging (BiCE™) platform, which uses single domain antibodies that bind to the complement protein C1q to activate the complement system, a fast-acting and potent part of the innate immune system. BiCE™ is a modular system that can arm antibodies to direct the complement system in a highly targeted way, so that it selectively kills cancer cells or immune cells that drive autoimmune diseases.

Commit is a spin-out from Aarhus University in Denmark, which has built a global reputation as a center of excellence in complement system biology over the last three decades. The Company was initially incubated and supported by the BioInnovation Institute in Denmark.

Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: “This financing from Novo Holdings and Bioqube Ventures validates our pioneering approach of engaging and activating the complement system for therapeutic purposes. Our BiCE™ platform gives us the ability to engage the complement system so that it attacks targeted cells in a highly selective manner. This platform also means we can use established antibodies, which cuts development times and reduces risk, to develop best-in-class therapeutics. This is a novel way of harnessing the immune system to tackle cancer and autoimmune disease, and we are confident in the tremendous potential it offers.”

Jeroen Bakker, Partner at Novo Holdings, said: “With over 30 years of academic rigor from leaders in the complement field behind it, Commit is now unlocking the potential of the complement system to transform the fight against cancer and autoimmune diseases. The team has an incredible track record of domain expertise, and we look forward to working with them to support them on their journey.”

Roderick Verhelst, Principal at Bioqube Ventures, said: “We believe Commit is doing something truly novel in the field of complement and advancing a technology with a multitude of therapeutic applications. Through its direct engagement of the complement system, this BiCE™ technology is a best-in-class approach for complement activation. The ability to arm conventional antibodies with potent complement activators for the development of targeted cell killing therapeutics is also a very attractive way of accelerating and derisking product development.”

Commit’s uniquely engineered and highly specific approach to triggering the complement system is expected to have a wide therapeutic index and broad applicability. BiCE™ technology is modular and active across multiple tumor-associated and target antigens. This approach to activating the immune system can be used in conjunction with other mechanisms of action, such as T-cell directed therapies or other targeted treatments. While antibody drug conjugates, T-cell engagers and CAR-Ts have made important advances in recent years, these approaches can be limited by toxicities, specific target density considerations, and - with T-cell directed therapies – T-cell exhaustion. The BiCE™ technology can potentially address these limitations to enable the development of effective therapeutic options for the treatment of cancer and autoimmune diseases.

   
Record changed: 2024-05-26

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Commit Biologics ApS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top